Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

Inclusion Criteria: * Subject has had stable moderate to severe plaque psoriasis for at least 6 months * Subject has involved body surface area (BSA) ≥ 10%, PASI ≥ 12, and sPGA ≥ 3 at screening and at baseline Exclusion Criteria: * Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, or other skin conditions at (eg, eczema) that would interfere with study evaluations * Subject has known history of Crohn's disease * Subject has any other significant concurrent medical condition or laboratory abnormalities, as defined in the study protocol * Subject has not stopped using certain psoriasis therapies as defined in the study protocol * Subject has previously used ustekinumab or any anti-IL-17 biologic therapy * Subject is pregnant or breastfeeding, or planning to become pregnant while enrolled in the study * Female subject is unwilling to use highly effective methods of birth control unless 2 years post-menopausal or surgically sterile